EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

EKTA.B

50.3

-3.08%↓

Search

BioArctic AB

Închisă

172.1 -3.85

Rezumat

Modificarea prețului

24h

Curent

Minim

172.1

Maxim

180.7

Indicatori cheie

By Trading Economics

Venit

-27M

-53M

Vânzări

25M

101M

EPS

-0.36

Marjă de profit

-52.845

Angajați

107

EBITDA

-24M

-43M

Statistici piață

By TradingEconomics

Capitalizare de piață

16B

Deschiderea anterioară

175.95

Închiderea anterioară

172.1

BioArctic AB Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 apr. 2025, 23:04 UTC

Top știri

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 apr. 2025, 22:40 UTC

Principalele dinamici ale pieței

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 apr. 2025, 22:18 UTC

Achiziții, Fuziuni, Preluări

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 apr. 2025, 18:51 UTC

Achiziții, Fuziuni, Preluări

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 apr. 2025, 22:22 UTC

Achiziții, Fuziuni, Preluări

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr. 2025, 22:21 UTC

Achiziții, Fuziuni, Preluări

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 apr. 2025, 21:43 UTC

Top știri
Câștiguri

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 apr. 2025, 20:34 UTC

Top știri

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 apr. 2025, 20:23 UTC

Top știri

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 apr. 2025, 20:15 UTC

Achiziții, Fuziuni, Preluări

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 apr. 2025, 18:38 UTC

Top știri

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 apr. 2025, 18:30 UTC

Top știri

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparație

Modificare preț

BioArctic AB Așteptări

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.